BNT162b2 vaccine induces moderate SARS-CoV-2 immunity in children 5 to
July 6, 2022
In a recent study published in the New England Journal of Medicine, researchers evaluated the effectiveness of the BNT162b2 vaccine against the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron in five to 11-year-old children. Only a few studies have evaluated the effectiveness of the …